
Nexus Spine Appoints David Ivanko as Vice President of Quality Engineering and Manufacturing and Andrew Shepherd as Vice President of Marketing
January 11, 2022
Nexus Spine announced key appointments to its leadership team that includes David Ivanko as Vice President of Quality Engineering and Manufacturing and Andrew Shepherd as Vice President of Marketing. The additions are part of a recently initiated strategy to move the company from a proof-of-concept phase to rapid commercialization of its novel compliant mechanism-based systems, consisting of PressON™ fixation, Tranquil™ interbody fusion, and upcoming technologies currently in development.
Mr. Ivanko brings more than 25 years of Quality and Manufacturing Engineering experience in the medical device industry to the organization. Prior to Nexus, he most notably served as Vice President of Quality Engineering for NuVasive, Inc. where he was responsible for all aspects of product quality from development to production to distribution.
Mr. Shepherd is also a highly accomplished veteran of the spinal implant industry that includes a lengthy career with Titan Spine where he served as Vice President of Marketing and was instrumental in establishing the surface technology segment in spine.
“I have long admired the quality of NuVasive products and instrumentation as well as the unique marketing approach of Titan Spine,” commented David Hawkes, President of Nexus Spine. “So, it made sense to me to pursue the two individuals responsible for those functions and combine their expertise with the technological capabilities and product portfolio of Nexus. I am very pleased to welcome Dave and Andrew to our leadership team as we begin to execute our comprehensive strategy to accelerate sales of our groundbreaking compliant mechanism-based systems.”
Read the original article here »
Contact:
Andrew Shepherd
andrew.shepherd@nexusortho.com
Recent News
- RefloDx Closes $2 Million Seed Round to Advance Noninvasive Testing for Chronic Throat and Voice Symptoms
- Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
- Ultragenyx sells second rare pediatric PRV in a week for $203M
- Co-Diagnostics’ Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing Forum
- Route 92 Medical Announces $100 Million Corporate Debt Facility
- Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp














